TerminatedPhase 2NCT03738800
A Safety, Efficacy and Systemic Exposure Study of CD5789 Cream in Adults and Adolescents With Lamellar Ichthyosis
Studying Autosomal recessive congenital ichthyosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Mayne Pharma International Pty Ltd
- Principal Investigator
- Keith A. Choate, MD, MDYale University
- Intervention
- CD5789 Cream 200 µg/g(drug)
- Enrollment
- 65 enrolled
- Eligibility
- 12 years · All sexes
- Timeline
- 2019 – 2021
Study locations (30)
- TCR Medical Corporation, San Diego, California, United States
- Children's Hospital Colorado, Aurora, Colorado, United States
- Yale University, New Haven, Connecticut, United States
- NorthShore University HealthSystem, Skokie, Illinois, United States
- Dawes Fretzin Clinical Research Group, LLC, Indianapolis, Indiana, United States
- DermAssociates, PC, Rockville, Maryland, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- Medical University of South Carolina, Charleston, South Carolina, United States
- Texas Dermatology and Laser Specialists, San Antonio, Texas, United States
- Eastern Health Monash University, Box Hill, Australia
- Veracity Clinical Research, Brisbane, Australia
- Royal Children's Hospital, Parkville, Australia
- Premier Specialists Ptd Ltd, Sydney, Australia
- The Hospital for Sick Children, Toronto, Canada
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03738800 on ClinicalTrials.gov